Federal Council approves Swissmedic's strategic goals for 2023–2026

Swissmedic guarantees efficient, independent therapeutic products oversight


At its meeting held on 9 December 2022, the Federal Council approved the strategic goals of the Swiss Agency for Therapeutic Products (Swissmedic) for 2023–2026. Efficient, independent therapeutic products oversight, expansion of national and international cooperation, and trustworthy communication with the public remain focal points. Greater emphasis will be placed on support for innovation and advancing digitalisation in the new strategy period.

Among other things, the goals stipulate that Swissmedic must constantly renew and expand its competencies so that it can keep pace with the many developments in its operating environment. The use of new technologies will further increase the effectiveness and efficiency of market surveillance of medicinal products and medical devices. In addition, Swissmedic will actively support the development of innovative therapeutic products, thereby promoting rapid access to novel therapies. Topics such as national and international cooperation and communication with the public will also continue to be of key importance.

Swissmedic is one of the leading therapeutic products agencies worldwide. One of its overarching aims is for Switzerland to continue to have efficient, independent therapeutic products oversight in the future. Swissmedic’s Agency Council prepares an annual report for the Federal Council on the achievement of the strategic objectives.

Address for enquiries

Media Unit

+41 58 462 02 76